GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » QSAM Biosciences Inc (OTCPK:QSAM) » Definitions » EPS without NRI

QSAM Biosciences (QSAM Biosciences) EPS without NRI : $-3,560.00 (TTM As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is QSAM Biosciences EPS without NRI?

QSAM Biosciences's earnings per share without non-recurring items for the three months ended in Dec. 2023 was $-180.00. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was $-3,560.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for QSAM Biosciences's EPS without NRI or its related term are showing as below:

QSAM' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -2189.7   Med: -13.5   Max: 74.4
Current: -337.2

QSAM's 3-Year EPS without NRI Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 5.5 vs QSAM: -337.20

QSAM Biosciences's EPS (Diluted) for the three months ended in Dec. 2023 was $-180.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3,560.00.

QSAM Biosciences's EPS (Basic) for the three months ended in Dec. 2023 was $-180.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3,560.00.


QSAM Biosciences EPS without NRI Historical Data

The historical data trend for QSAM Biosciences's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

QSAM Biosciences EPS without NRI Chart

QSAM Biosciences Annual Data
Trend Mar14 Mar15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.39 -40.44 -17.01 -5,381.18 -3,380.00

QSAM Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,399.94 -1,800.00 -860.00 -720.00 -180.00

Competitive Comparison of QSAM Biosciences's EPS without NRI

For the Biotechnology subindustry, QSAM Biosciences's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


QSAM Biosciences's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, QSAM Biosciences's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where QSAM Biosciences's PE Ratio without NRI falls into.



QSAM Biosciences EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3,560.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


QSAM Biosciences  (OTCPK:QSAM) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


QSAM Biosciences EPS without NRI Related Terms

Thank you for viewing the detailed overview of QSAM Biosciences's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


QSAM Biosciences (QSAM Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
9442 Capital of Texas Highway North, Plaza 1, Suite 500, Austin, TX, USA, 78759
QSAM Biosciences Inc is a clinical-stage novel radiopharmaceutical company. The company is developing treatments for bone cancer and related diseases.
Executives
Adam King officer: Chief Financial Officer 9442 CAPITAL OF TEXAS HWY N, PLAZA 1, SUITE 500, AUSTIN TX 78759
Link Jr. Charles J director C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AIMES IA 50010
Adriann Sax director 7 DORSET COURT,, EAST BRUNSWICK, NJ 08816
David Charles Link director 2100 E 54TH STREET NORTH, SIOUX FALLS SD 57104
Douglas R Baum director, officer: CEO & Director 5000 RAFFEE COVE, AUSTIN TX 78731-1132
C Richard Piazza director, officer: Executive Chairman 2236 EAST MALL, SUITE 208, UNIVERSITY OF BRITISH COLUMBIA, VANCOUVER A1 V6T 1Z3
Checkmate Strategic Capital Holdings, Llc other: Member of 13(d) 10% owner grp 595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101
Checkmate Strategic Capital 2, Llc 10 percent owner, other: See Explanation of Responses 595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101
Checkmate Capital Group, Llc 10 percent owner, other: Member of 13(d) 10% owner grp 595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101
Charles Thomas Paschall other: Member of 13(d) 10% owner grp 595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101
Christopher M. Nelson director, officer: General Counsel 420 ROYAL PALM WAY, SUITE #100, PALM BEACH FL 33480
Scott W. Whitney director, other: Former Director 96 WINDSOR DRIVE, PINE BROOK NJ 07058
Kevin Bolin director, officer: Former Chairman & CEO 1081 ROSEDALE DRIVE, ATLANTA GA 30306
Tristan Peitz director, other: Former Director C/O Q2POWER TECHNOLOGIES, INC., 420 ROYAL PALM WAY, #100, PALM BEACH FL 33480
Joel David Mayersohn director 350 EAST LAS OLAS BLVD. #1150, FORT LAUDERDALE FL 33301

QSAM Biosciences (QSAM Biosciences) Headlines

From GuruFocus